GHK-Cu is not an FDA approved drug and is not on the list of substances US pharmacies may compound. Since 14 May 2026 the FDA lists it as under evaluation, but only for non-injectable routes, and plans to take it to its compounding committee before the end of February 2027. Injectable GHK-Cu has no such status.

The short version. GHK-Cu is not FDA approved and is not on the 503A Bulks List. Since 14 May 2026 the FDA has it under evaluation again, but only for non-injectable routes, with a committee review planned before the end of February 2027. Injectable GHK-Cu is outside that, and the HHS draft policy of October 2026 does not name it.
GHK-Cu is a tripeptide of glycine, histidine and lysine bound to a copper ion, also sold as copper peptide or copper tripeptide-1. GHK occurs naturally in human plasma, and a 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences puts the plasma level at about 200 ng/mL at age 20, falling to 80 ng/mL by age 60. That decline is the core of how GHK-Cu is marketed: replace what age takes away. The same review describes laboratory findings on collagen, elastin, blood vessel growth and gene expression. Both authors list R&D Skin Biology as their affiliation, and most of the cell and gene work it summarises has not been reproduced in controlled human trials.
GHK-Cu lives in two markets that follow different rules. In cosmetics, copper peptide has been an ingredient in creams and serums for decades, and the FDA says what decides whether a product is a cosmetic or a drug is its intended use: a cream sold to improve how skin looks is a cosmetic, and one sold to treat a condition is a drug. In the peptide market, GHK-Cu is sold online as an injection for skin, hair, healing and ageing, often in blends with BPC-157 and TB-500. The FDA NDC Directory lists GHK-Cu only as a bulk ingredient, including one listing for prescription compounding, and no finished approved drug.

In plain EnglishGHK-Cu is a tiny protein fragment carrying copper. Your blood has some naturally. Creams with it are ordinary cosmetics. Injections of it are a different matter, and no US drug containing it has ever been approved.
GHK-Cu's legal position in 2026 splits by route, and the split comes from one FDA document. The FDA's list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, says GHK-Cu, except for injectable routes, was removed from Category 1 on 22 April 2026 because its nominations were withdrawn. On 5 May 2026 one nominator clarified that it had meant to withdraw only the injectable route, so the FDA added GHK-Cu (except for injectable routes) back to Category 1, the group it labels "under evaluation", and said it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 on adding GHK-Cu to the 503A Bulks List.
| Question | What the record says | Source |
|---|---|---|
| FDA approved product? | None. Listed only as a bulk ingredient | Drugs@FDA and NDC Directory, 13 Nov 2026 |
| On the 503A Bulks List? | No | No proposed or final rule |
| Non-injectable routes | Category 1, under evaluation, again since May 2026 | FDA nominated substances list, 14 May 2026 |
| Injectable routes | Previously Category 2; nomination withdrawn | FDA safety-risk page, current as of 22 Apr 2026 |
| Committee review | Planned before the end of February 2027 | FDA nominated substances list, 14 May 2026 |
| HHS draft policy | Not named among the six peptides | FR Doc. 2026-22192; BakerHostetler, 28 Oct 2026 |
Injectable GHK-Cu sits on the other side of that line. The FDA page on bulk substances that may present significant safety risks, current as of 22 April 2026, lists "GHK-Cu (for injectable routes of administration)" among substances previously in Category 2 whose nominations were withdrawn. Its stated concern is that compounded injectable GHK-Cu may pose a risk of immune reactions because of aggregation and peptide-related impurities, and that there are limited human data to inform safety. Leaving Category 2 by withdrawal is not a finding that the risk went away, and no document puts injectable GHK-Cu into Category 1. Category 1 itself is not the 503A list: it means the FDA has not finished deciding.

In plain EnglishThe FDA is still weighing GHK-Cu for creams and other non-injected forms, and plans to ask its expert committee by February 2027. Injections were pulled from that review after the FDA had flagged them as a safety concern. Neither is an approval.
GHK-Cu is marketed online as an injection. The only route the FDA is still evaluating is the one that does not involve a needle.
The HHS draft policy is where GHK-Cu is most often misplaced. On 30 October 2026 HHS published FR Doc. 2026-22192, a draft and non-binding enforcement discretion policy for 503A compounding with certain peptides while the FDA builds the 503A list. BakerHostetler, summarising its appendix on 28 October 2026, lists six: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. GHK-Cu is not among them, and it was not one of the seven peptides the committee voted on in July 2026. A Federal Register search on 13 November 2026 found no committee meeting notice for GHK-Cu yet. The Ozemback peptide legal status tracker keeps GHK-Cu in its own row, and will change it the day the FDA schedules that review. You can also test yourself with the approved, recommended or neither quiz.
The controlled human evidence is two small topical trials, decades apart, pointing in different directions. We found no published trial of injected GHK-Cu.

The strongest result is also the oldest. In 1994 Mulder and colleagues published a multicenter, randomized, evaluator-blinded, placebo-controlled trial of Iamin Gel, a GHK-Cu gel, in diabetic foot ulcers, in Wound Repair and Regeneration. With standard wound care in both arms, plantar ulcers treated with the gel reached a median 98.5% closure against 60.8% with the vehicle, and ulcer infections fell to 7% from 34%. The product followed the medical device path: the FDA cleared Iamin Gel Wound Dressing for Procyte Corp. under 510(k) K953853 on 5 February 1996, as substantially equivalent for some indications. A device clearance for a wound dressing says nothing about injecting the peptide, and Drugs@FDA lists no approved GHK-Cu drug.
The cosmetic evidence is weaker than its marketing. In the 2006 randomized trial by Miller and colleagues in Archives of Facial Plastic Surgery, 13 patients completed a comparison of skin care with and without GHK-Cu after CO2 laser resurfacing. Computer analysis and blinded evaluators found no significant difference in redness or wrinkles; only patient satisfaction was higher with GHK-Cu (P = .04). The Pickart review cites larger results, such as a 12-week cream study in 71 women and a 31.6% cut in wrinkle volume against another peptide, but only in summary, without the full data. In the lab, Hostynek and colleagues showed copper from GHK-Cu does cross isolated human skin, which says delivery is possible, not that it works.
In plain EnglishA copper peptide gel helped diabetic foot ulcers close in one 1990s trial and was sold as a wound dressing. For wrinkles, the one small randomized trial found no measurable change. We found no published trial of injecting it.
The safety record splits by route like the legal one. On skin, a 2016 cell study by Li and colleagues in Scientific Reports found GHK-Cu was not cytotoxic and did not raise skin irritation markers, unlike copper chloride and copper acetate at the same concentrations. For injections, the FDA says data in humans are limited and flags immune reactions from aggregation and impurities. FAERS, via openFDA data updated 28 October 2026, holds two reports naming GHK-Cu, both marked serious and both with other products reported alongside: one with sermorelin and BPC-157, listing anaphylactic shock, and one with a blend labelled GHK-Cu, BPC-157 and TB-500 plus Ozempic and hCG, listing a lymphoid cancer. Neither report shows that GHK-Cu caused anything.
There is no FDA approved dose of GHK-Cu, because there is no FDA approved drug.
Every GHK-Cu injection dose you will find in the US comes from somewhere other than a US label or a published trial. The 1994 ulcer trial applied a metered dose of gel to the wound daily, and the 2006 trial used commercial skin care products, so neither gives a figure that translates to an injection. The FDA nominated substances list does not set doses, and the injectable nomination was withdrawn before any evaluation was published. Concentrations printed on cosmetic labels describe a cream, not a drug dose. We report this because it is the record, and we do not publish a recommended dose, cycle or protocol for GHK-Cu or any other compound, for any route.

Check whether the page uses cosmetic or cell results to sell injections; the human trials in the record are topical, and the injectable route is the one the FDA flagged. Check whether it says GHK-Cu is "legal" or "FDA approved" without naming a route; only non-injectable GHK-Cu is under evaluation, and evaluation is not approval. Check whether it lumps GHK-Cu in with the HHS peptide policy; the October 2026 draft does not name it. Check who pays the author: nearly every site ranking for GHK-Cu injections or dosage sells it, sells a consultation or links to a seller. This page carries a date at the top, 13 November 2026, so you can tell when it stops being current. Related files: BPC-157, TB-500 and KPV.
GHK-Cu is not an FDA approved drug and is not on the 503A Bulks List. In its list updated 14 May 2026 the FDA placed GHK-Cu, except for injectable routes, back in Category 1, the group of nominated substances it is still evaluating, and said it intends to consult its compounding committee before the end of February 2027. It is also sold in cosmetics. Whether a specific seller is acting lawfully is a question for a lawyer.
Injectable GHK-Cu is outside the FDA evaluation. The nominator withdrew the injectable route, and the FDA safety-risk page lists GHK-Cu for injectable routes among substances previously in Category 2, citing a risk of immune reactions from aggregation and peptide-related impurities. The HHS draft policy of 30 October 2026 does not name GHK-Cu at all.
No. A search of Drugs@FDA returns no approved product, and the FDA NDC Directory lists GHK-Cu only as a bulk ingredient. A GHK-Cu gel, Iamin Gel, was cleared in 1996 as a wound dressing under the medical device route, which is not a drug approval.
The controlled evidence is thin. The only PubMed record tagged as a trial in our search followed 13 patients after laser resurfacing and found no objective difference in redness or wrinkles, though patients using GHK-Cu rated their skin higher. Larger cosmetic results are reported in reviews by authors from a skin care company.
There is no FDA approved dose, because there is no FDA approved drug. Injection figures on pages that rank for this query come from sellers and clinics, not from a US label or a published trial. We do not publish a dose, cycle or protocol for this or any compound.
For injections, largely unknown. The FDA says there are limited human data and flags immune reactions. FAERS holds two reports naming GHK-Cu, both serious and both with other peptides reported alongside, so neither shows that GHK-Cu caused anything. On skin, a cell study found GHK-Cu less irritating than plain copper salts.
No. The draft policy of 30 October 2026 names BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c, as summarised by BakerHostetler. The peptide legal status tracker carries GHK-Cu separately, with the date of each fact.
Whatever you decide, your own numbers are the one part of this that is not contested. A baseline panel costs less than a month of most things sold in this category and it is yours to keep.
Ozemback is not a provider and takes no part in any clinical decision. The link above is an affiliate link: if you buy a panel through it we receive a commission at no additional cost to you. We are paid for the referral, never for the result, and it does not change what we publish.